Trial · NCT03905330
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change in the Average Morning ItchRO(Obs) Severity Score in the Primary Cohort | Primary Cohort Maralixibat | -1.718 | 95% Confidence Interval -2.272 to -1.163 | Score on a scale | |
| Mean Change in the Average Morning ItchRO(Obs) Severity Score in the Primary Cohort | Primary Cohort Placebo | -0.628 | 95% Confidence Interval -1.136 to -0.121 | Score on a scale | |
| Mean Change in Total sBA Level in the Primary Cohort. | Primary Cohort Maralixibat | -175.536 | 95% Confidence Interval -256.716 to -94.356 | μmol/L | |
| Mean Change in Total sBA Level in the Primary Cohort. | Primary Cohort Placebo | 11.187 | 95% Confidence Interval -58.073 to 80.446 | μmol/L | |
| Mean Change in the Average Morning ItchRO(Obs) Severity Score in Participants With PFIC (PFIC1, Nt-PFIC2, PFIC3, PFIC4 and PFIC6) | PFIC Cohort Maralixibat | -1.811 | 95% Confidence Interval -2.178 to -1.444 | score on a scale | |
| Mean Change in the Average Morning ItchRO(Obs) Severity Score in Participants With PFIC (PFIC1, Nt-PFIC2, PFIC3, PFIC4 and PFIC6) | PFIC Cohort Placebo | -0.610 | 95% Confidence Interval -1.000 to -0.221 | score on a scale | |
| Mean Change in Total sBA Level in Participants With PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6) | PFIC Cohort Maralixibat | -157.489 | 95% Confidence Interval -200.276 to -114.703 | μmol/L | |
| Mean Change in Total sBA Level in Participants With PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6) | PFIC Cohort Placebo | 2.913 | 95% Confidence Interval -42.320 to 48.146 | μmol/L | |
| Proportion of ItchRO(Obs) Responders in the Primary Cohort | Primary Cohort Maralixibat | 8 | Number of responders | ||
| Proportion of ItchRO(Obs) Responders in the Primary Cohort | Primary Cohort Placebo | 4 | Number of responders | ||
| Proportion of sBA Responders in the Primary Cohort | Primary Cohort Maralixibat | 5 | Number of responders | ||
| Proportion of sBA Responders in the Primary Cohort | Primary Cohort Placebo | 1 | Number of responders | ||
| Proportion of ItchRO(Obs) Responders PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6) | PFIC Cohort Maralixibat | 21 | Number of responders | ||
| Proportion of ItchRO(Obs) Responders PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6) | PFIC Cohort Placebo | 8 | Number of responders | ||
| Proportion of sBA Responders PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6) | PFIC Cohort Maralixibat | 15 | Number of responders | ||
| Proportion of sBA Responders PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6) | PFIC Cohort Placebo | 2 | Number of responders |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03905330/results